Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

— Study met primary endpoint: Enobosarm treatment resulted in statistically significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) — — Patients on Enobosarm on average lost 71% less lean mass than patients receiving WEGOVY alone — — Patients on Enobosarm on average lost 27% more fat mass than patients receiving WEGOVY alone – — Enobosarm improved body composition as mean total body weight loss was similar compared to subjects receiving WEGOVY alone — — Enob

This article was originally published here.